Skip to content

Finding Novel Inhibitors of FMS-like Tyrosine Kinase 3 from Selected FDA-approved Anticancer Drugs: Insights from Molecular Docking, MD Simulations, and ADMET Profiling.

Oct 2026 · Current Medicinal Chemistry · 0 citations
Medicine

Abstract

Background

Wild-type FLT3 (WT-FLT3) has emerged as a relevant molecular target in Acute Myeloid Leukemia (AML), with increasing evidence implicating its role in leukemic proliferation and resistance, even in the absence of FLT3 mutations. Although gilteritinib is an approved FLT3 inhibitor, its efficacy in WT-FLT3 AML remains limited, underscoring the need for alternative strategies.

Method

We filtered 1,737 FDA-approved anticancer agents from the Selleckchem database using computational techniques to identify possible WT-FLT3 inhibitors. A total of 118 druglike compounds were docked against the WT-FLT3 binding site as determined by gilteritinib using AutoDock Vina; ADMET screening and MD simulations of 150 ns were executed on hit compounds using the ADMETSar server and GROMACS software, respectively.

Results

In the end, 56 compounds with binding energies between -8.0 and -10.3 kcal/- mol were obtained, while the control, gilteritinib, returned -6.4 kcal/mol. Among this subset, Amlexanox (-9.5), sanguinarine (-10.3), crizotinib (-9.7), (S)-crizotinib (-9.7), and rutaecarpine (-10.0) showed high predicted affinity. Predictions from ADMET and 150 ns MD simulations indicated that amlexanox had stable, specific interactions with the WT-FLT3 active site, superior ADMET, and a concentrated free-energy basin with increased conformational stability. In contrast, sanguinarine and others raised significant toxicity risks.

Conclusion

These results suggest amlexanox is a potential new repurposing agent as a WT-FLT3 inhibitor in AML. This potential outcome needs urgent experimental confirmation through in vitro and in vivo models.

View source

Similar papers

Sep 2026

Structure-Based Optimization of 2-Aminopyrimidine Derivatives as Potent Multi-target FLT3/CHK1/IRAK4 Inhibitors for Acute Myeloid Leukemia.

The efficacy of FLT3 inhibitors is limited by resistance. Co-inhibiting FLT3 and CHK1 can overcome FLT3i resistance, and IRAK4 signaling contributes to leukemic cell survival in FLT3-mutant acute myeloid leukemia (AML). We discovered a novel series of 2-aminopyrimidine derivatives as potent multi-target FLT3/CHK1/IRAK4...

Xue-Mei Li, Kai-Long Jiang, Lu-Yao Zhang et al. · 0 citations
Oct 2026

Structure-based drug repurposing for CDK6: Molecular docking and molecular dynamics characterization of FDA-approved non-oncological compounds.

Structural, conformational, energetic, and pharmacokinetic characterization of dutasteride, danazol, and azelastine as candidate CDK6-binding scaffolds are provided.

Syarifuddin Husain, Ruzianisra Mohamed, Khairul Bariyyah Abd. Halim et al. · 0 citations
Open access Nov 2026

Computational Identification and Prioritization of Novel Tankyrase 1 and 2 Inhibitor Candidates Through Structure-Based Design, ADMET Profiling, and Long-Timescale Molecular Dynamics

Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes and is frequently associated with aberrant activation of the Wnt/β-catenin signaling pathway. Because tankyrase 1 and 2 (TNKS1/2) promote Wnt pathway activation through the regulation of AXIN stability, these enzymes represen...

Oscar Saurith-Coronell, Olimpo Sierra-Hernandez, Carlos Vargas-Echeverría et al. · 0 citations
Open access Nov 2026

Synthesis, in silico studies, and in vitro evaluation of novel isoindigo inhibitors targeting wild-type and D835Y mutant FLT3

FMS-like tyrosine kinase 3 (FLT3) is a validated therapeutic target, but resistance mutations such as D835Y compromise its therapeutic utility by conferring resistance to existing inhibitors and limiting therapeutic options in FLT3-driven cancers, such as Acute Myeloid Leukemia (AML). In order to address this challenge...

Mohammed M. Abadleh, A. H. Abdullah, Ahmed Adel et al. · 0 citations
Sep 2026

Design, synthesis and biological evaluation of a series of new, potent FLT3 PROTAC degraders with rigid linkers.

Fms-like tyrosine kinase 3 (FLT3), a member of the type III receptor tyrosine kinase family, is identified as a promising drug target for treatment of acute myeloid leukemia (AML). Here, we designed and synthesized a series of new FLT3 PROTAC degraders by incorporating rigid linkers between gilteritinib and CRBN ligand...

Li-Cheng Zhou, Ying-Long Chen, Jia-He Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.